Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,029 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,029 Papers indexed
1,440 Papers AI scored
40,029 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40029 results
B
Trends in physical functioning in acute lymphoblastic leukemia and non-Hodgkin lymphoma survivors across three decades.
PMID 37938431 Published: 2023-11-08 Ingested: 2026-08-02 12:12 AM Journal of cancer survivorship : research and practice
AI -
Standard 75.8
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.8/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 44.0; sample size: 20.0; recency: 80.0; abstract quality: 100.0.

AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.8/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 86.4; sample size: 50.0; recency: 100.0; abstract quality: 100.0.

B
131I-mIBG therapy in relapsed/refractory neuroblastoma: an old bridge to the future.
PMID 40187111 Published: 2025-04-04 Ingested: 2026-08-02 12:04 AM ESMO open
AI -
Standard 75.78
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.8/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 96.4; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

B
[Clinical analysis of treatment free remission outcomes after discontinuation of tyrosine kinase inhibitors in childhood chronic myeloid leukemia].
PMID 39979103 Published: 2025-03-02 Ingested: 2026-08-02 12:04 AM Zhonghua er ke za zhi = Chinese journal of pediatrics
AI -
Standard 75.76
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.8/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 73.8; sample size: 30.0; recency: 90.0; abstract quality: 100.0.

B
N-terminal Pro-brain Natriuretic Peptide as a Prognostic Biomarker for Cardiac Surgeries: A Systematic Review.
PMID 41196806 Published: 2026-01-01 Ingested: 2026-08-02 12:06 AM Brazilian journal of cardiovascular surgery
AI -
Standard 75.75
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.8/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 38.8; sample size: 60.0; recency: 100.0; abstract quality: 85.0.

B
Asparaginase-Based Treatment Modifications and their effect on Pediatric Acute Lymphoblastic Leukemia Outcomes: A Single-Center Experience.
PMID 42460761 Published: 2026-07-16 Ingested: 2026-08-02 12:07 AM Turkish journal of haematology : official journal of Turkish Society of Haematology
AI -
Standard 75.74
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.7/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 76.2; sample size: 70.0; recency: 100.0; abstract quality: 100.0.

B
Everolimus and sirolimus in the treatment of cardiac rhabdomyomas in neonates.
PMID 40287604 Published: 2025-04-26 Ingested: 2026-08-02 12:04 AM Pediatric research
AI -
Standard 75.74
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 75.7/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 46.2; sample size: 40.0; recency: 90.0; abstract quality: 100.0.

Previous
Page 361 of 3336
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic